secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biohaven Ltd. (BHVN)
CIK:        0001935979
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001935979-22-000009
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biohaven posts Q3 net loss $68.9M; launches post-Pfizer with $257.8M cash, raises $301.9M offering
--------------------------------------------------------------------------------

- Net loss of $68.9M ($1.75/share) vs $54.4M loss in Q3 2021; non-GAAP adjusted loss $49.2M ($1.25/share).
- Cash at Sept 30: $50.7M; post-spin-off and $301.9M public offering, pro-forma cash ~$541M with no debt.
- Spin-off from Pfizer completed Oct 3, 2022; BHVN began trading independently with $257.8M cash.
- Closed public offering of 28.75M shares at $10.50/share, gross proceeds $301.9M (net $282.8M).
- Pipeline milestones: BHV-7000 Phase 1 complete H1 2023; troriluzole Phase 3 OCD enrollment in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1935979/000193597922000009/0001935979-22-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1935979/000193597922000009/bhvn-20221109.htm
  HTML page:      https://secwatch.observer/filing/0001935979-22-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer